Alan works to develop gene editing technologies for therapeutic use, contributing to the next generation of genetic medicines at Life Edit.
He attained his PhD in Bioengineering from Rice University where he focused on the development of CRISPR-based transcriptional activators and the prediction of transcriptional outcomes associated with CRISPR-based epigenetic editing.
.svg)
.svg)
To rewrite the future by curing disease, making any edit, anywhere.
To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.
We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.
